Information Provided By: 
Fly News Breaks for February 6, 2017
MYGN
Feb 6, 2017 | 08:12 EDT
UBS analyst Jonathan Groberg took a fresh look at Myriad Genetics and concluded it is still too early to become constructive on the stock. He reiterated his Sell rating, citing the company's higher prices versus competitors, his view that diversification from newer tests will take time to materialize, and the fact that he sees no obvious accretive uses for its cash rich balance sheet. Groberg lowered his price target to $14 from $18 on Myriad Genetics shares.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
